NCT02574923
Completed
Phase 2
Outcomes of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy: A Self-Controlled Clinical Trial
Vinmec Healthcare System1 site in 1 country30 target enrollmentNovember 5, 2015
ConditionsCerebral Palsy
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Cerebral Palsy
- Sponsor
- Vinmec Healthcare System
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Change in Total Score of Gross Motor Function Measure (GMFM)-88
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The aim of this study is to assess the safety and effectiveness of autologous bone marrow mononuclear stem cells in patients with cerebral palsy.
Detailed Description
The aim of this study is to assess the safety and effectiveness of autologous bone marrow mononuclear stem cells in 30 patients with cerebral palsy at Vinmec International Hospital, Hanoi, Vietnam.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Cerebral palsy of any types caused by oxygen deprivation.
Exclusion Criteria
- •Hydrocephalus with ventricular drain
- •Coagulation disorders
- •Allergy to anesthetic agents
- •Severe health conditions such as cancer, failure of heart, lung, liver or kidney
- •Active infections
Outcomes
Primary Outcomes
Change in Total Score of Gross Motor Function Measure (GMFM)-88
Time Frame: 3 months and 6 months after transplantation
GMFM-88
Change in Gross Motor Function Measure (GMFM)-66 Percentile
Time Frame: 3 months and 6 months after transplantation
GMFM-66 percentile
Secondary Outcomes
- Change in Quality of Life(3 months and 6 months after transplantation)
- Change in Denver Developmental Score(3 months and 6 months after transplantation)
- Number of adverse events(Through study completion, an average of 6 months)
- Change in Muscle tone(3 months and 6 months after transplantation)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Outcomes of Stem Cells for Cerebral PalsyCerebral PalsyNCT02569775Vinmec Healthcare System40
Completed
Phase 2
Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary AtresiaLiver Cirrhosis, BiliaryNCT03468699Vinmec Research Institute of Stem Cell and Gene Technology17
Completed
Phase 1
Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT01677013Peking University Aerospace Centre Hospital1,026
Completed
Phase 1
Outcomes of Autologous Bone Marrow Mononuclear Cell Administration in the Treatment of Neurologic Sequelea in Children With Spina BifidaStem Cell InfusionNCT05472428Vinmec Research Institute of Stem Cell and Gene Technology11
Completed
Phase 1
Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological SequelaeSequelae of Injuries of HeadNCT05293873Vinmec Research Institute of Stem Cell and Gene Technology50